Fig. 4From: Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstructionComparison in the change seen over 12 months of treatment in 10 subjects treated with LUM/IVA. This is compared to the change seen in 10 age matched historical controls over a 12 month period of review. Data is represented as mean and standard deviation. Comparison made using Student’s T testBack to article page